BRIEF-Revance Therapeutics plans to initiate global phase 3 program in second half of 2016

Thu Jul 14, 2016 4:20pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 14 (Reuters) - Revance Therapeutics Inc :

* Revance Announces Completion Of Pre-Phase 3 meeting with FDA for rt002 injectable to treat glabellar lines

* Company plans to initiate global phase 3 program in second half of 2016

* Co's phase 3 program will include two placebo-controlled pivotal studies conducted at multiple sites in US and Canada Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)